EVIDENCE PROFILE / PUBLISHED
Retatrutide
Retatrutide is an investigational agonist at GIP, GLP-1, and glucagon receptors. Randomized phase 2 trials reported metabolic effects and frequent gastrointestinal adverse events. A peer-reviewed phase 3 type 2 diabetes trial was published in 2026; topline announcements should be distinguished from peer-reviewed trial reports.
Evidence at a glance
- Human
- SubstantialSeveral randomized trials (phase 2 and phase 3) of an investigational medicine.
- Animal/cell
- Not rated
- Approved medicine
- Not rated
Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.
PREPPY BOY ASKS
“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”
The catalogue name is a starting point, not proof of formulation or identity. Clinical development studies weight, glycemic, liver, and cardiometabolic outcomes.
Identity
Retatrutide is an investigational agonist at GIP, GLP-1, and glucagon receptors.
Biological mechanism or research interest
Clinical development studies weight, glycemic, liver, and cardiometabolic outcomes.
Verified approved human uses
The reviewed phase 2 and phase 3 trial records describe investigational retatrutide; they do not establish marketing approval or validate catalogue material.
Investigational human evidence
Randomized phase 2 trials reported metabolic effects and frequent gastrointestinal adverse events. A peer-reviewed phase 3 type 2 diabetes trial was published in 2026; topline announcements should be distinguished from peer-reviewed trial reports.
Popular claims versus demonstrated findings
Calling retatrutide superior, a best seller, or clinically effective outside the studied populations and development program is unsupported.
Human versus animal or cell evidence
Receptor rationale and animal pharmacology do not replace confirmatory clinical trials.
Limitations and known risks
Long-term benefit-risk, rare events, applicability beyond studied populations, and formulation quality for unverified catalogue material remain unresolved.
